Correlation between Factor VIII Genotype and Inhibitor Development in Hemophilia A

ABSTRACT

The development of neutralizing antibodies, or inhibitors, against infused factor VIII represents a significant complication of treatment for hemophilia A. Although it is likely that both genetic and environmental factors influence whether patients form inhibitors, correlations between types of factor VIII mutations and inhibitor development are becoming apparent. Approximately 20% of all patients with severe hemophilia A generate inhibitors. Of these inhibitor patients, 90% have inversions, large deletions or nonsense mutations of the factor VIII gene that would be predicted to eliminate production of factor VIII antigen. In contrast to patients with severe disease, inhibitor formation in patients with mild/moderate hemophilia A is rare. Inhibitor patients with mild/moderate disease typically have missense mutations that may cause local conformational changes within immunogenic domains of factor VIII and lead to production of dysfunctional antigen. Taken together, hemophilia A patients are predisposed to inhibitor development with mutations causing infused factor VIII to be perceived as either 1) a completely novel antigen or 2) an immunologically altered antigen.

KEYWORD

Hemophilia A - factor VIII gene - factor VIII mutation - inhibitor

REFERENCES

• 1 Tuddenham E G, Cooper D N, Gitschier J. Haemophilia A: Database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene.  Nucleic Acids Res . 1991;  19 4821-4833
• 2 Tuddenham E G, Schwaab R, Seehafer J. Haemophilia A: Database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene.  Nucleic Acids Res . 1994;  22 4851-4868
• 3 Antonarakis S E, Kazazian H H, Tuddenham E G. Molecular etiology of factor VIII deficiency in hemophilia A.  Hum Mutat . 1995;  5 1-22
• 4 Ehrenforth S, Kreuz W, Scharrer I. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.  Lancet . 1992;  339 594-598
• 5 Addiego J, Kasper C, Abildgaard C. et al.  Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet . 1993;  342 462-464
• 6 Lusher J M, Arkin S, Abildgaard C F, Schwartz R S. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.  N Engl J Med . 1993;  328 453-459
• 7 Bray G L, Gomperts E D, Courter S. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.  Blood . 1994;  83 2428-2435
• 8 Schwaab R, Brackmann H H, Meyer C. Haemophilia A: Mutation type determines risk of inhibitor formation.  Thromb Haemost . 1995;  74 1402-1406
• 9 Giannelli F, Green P M, Naylor J A. A genetic view on the etiology of the inhibitor complication.  Blood . 1996;  87 (Letter) 2612
• 10 Hoyer L W. Why do so many haemophilia A patients develop an inhibitor?.  Br J Haematol . 1995;  90 498-501
• 11 Tuddenham E G, McVey J H. The genetic basis of inhibitor development in haemophilia A.  Haemophilia . 1998;  4 543-545
• 12 Hay C R. Why do inhibitors arise in patients with haemophilia A?.  Br J Haemotol . 1999;  105 584-590
• 13 Naylor J A, Green P M, Rizza C R, Giannelli F. Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients.  Human Mol Genet . 1993;  2 11-17
• 14 Goodeve A C, Preston F E, Peake I R. Factor VIII gene rearrangements in patients with severe haemophilia A.  Lancet . 1994;  343 329-330
• 15 Tizzano E F, Altisent C, Tusell J, Domenech M, Baiget M. Intron 22 inversions and haemophilia.  Lancet . 1994;  343 792
• 16 Ljung R, Sjorin E. Inversions of the factor VIII gene in Swedish patients with severe haemophilia A.  Eur J Haemotol . 1995;  54 310-313
• 17 Poon M C, Low S, Sinclair G D. Factor VIII gene rearrangement analysis and carrier determination in hemophilia A.  J Lab Clin Med . 1995;  125 402-406
• 18 Antonarakis S E, Rossiter J P, Young M. Factor VIII gene inversions in severe hemophilia A: Results of an international consortium study.  Blood . 1995;  86 2206-2212
• 19 Weinmann A F, Schoof J M, Thompson A R. Clinical correlates among 49 families with hemophilia A and factor VIII gene inversions.  Am J Hematol . 1996;  51 192-199
• 20 Lakich D, Kazazian Jr H H, Antonarakis S E, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A.  Nat Genet . 1993;  5 236-241
• 21 McMillan C W, Shapiro S S, Whitehurst D. The natural history of factor VIII:C inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors.  Blood. . 1988;  71 344-348
• 22 Hoyer L W. The factor VIII complex: Structure and function.  Blood . 1981;  58 1-13
• 23 Kemball-Cook G, Tuddenham E GD, Wacey A I. The factor VIII structure and mutation resource site: HAMSTeRS version 4.  Nucleic Acids Res . 1998;  26 216-219
• 24 Hay C R, Ludlam C A, Colvin B T. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.  Thromb Haemost . 1998;  79 762-766
• 25 Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer L W. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting.  Thromb Haemost . 1992;  67 665-671
• 26 Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2.  Blood . 1993;  82 1767-1775
• 27 Fijnvandraat K, Turenhout E A, van den Brink N E. The missense mutation Arg593→Cys is related to antibody formation in a patient with mild hemophilia A.  Blood . 1997;  89 4371-4377
• 28 van den Brink N E, Timmermans S M, Turenhout E A. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593→Cys substitution.  Thromb Haemost . 1999;  81 723-726
• 29 Thompson A R, Murphy M E, Liu M. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation.  Blood . 1997;  90 1902-1910
• 30 Peerlinck K, Jacquemin M G, Arnout J. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.  Blood . 1999;  93 2267-2273
• 31 Hay C R, Ollier W, Pepper L. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party.  Thromb Haemost . 1997;  77 234-237
• 32 Oldenburg J, Picard J K, Schwaab R. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII.  Thromb Haemost . 1997;  77 238-242